Stage I Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia
This phase II trial is studying how well dasatinib works in treating patients with unresectable or metastatic squamous cell skin cancer or RAI Stage 0-I chronic lymphocytic leukemia. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PRIMARY OBJECTIVES:
I. Determine the objective response rate (complete response and partial response) in
patients with unresectable or metastatic squamous cell carcinoma of the skin or RAI stage
0-I chronic lymphocytic leukemia receiving dasatinib.
SECONDARY OBJECTIVES:
I. Determine the progression-free survival of patients receiving this drug. II. Evaluate
tumor for presence of total EphA2 and both total and active Src and FAK by
immunohistochemistry (IHC) pre-treatment with dasatinib.
III. Evaluate tumor for presence of cyclooxygenase-2 by IHC pre-treatment with dasatinib.
OUTLINE: Patients are assigned to 1 of 2 treatment arms.
ARM I: Patients receive 100 mg dasatinib orally (PO) twice daily (BID) on days 1-28.
ARM II (PATIENTS ENROLLED AFTER 11/18/08): Patients receive 70 mg dasatinib PO BID on days
1-28.
In both arms, courses repeat every 28 days in the absence of disease progression or
unacceptable toxicity.
Pre-therapy tumor biopsy specimens are collected to detect total and phosphorylated Src and
FAK, total EphA2, and cyclooxygenase-2 by immunohistochemistry.
After completion of study treatment, patients are followed up monthly for up to 12 weeks.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01093586 -
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
|
Phase 2 | |
Terminated |
NCT00387426 -
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
|
Phase 2 | |
Terminated |
NCT00377104 -
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT01441882 -
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT00288067 -
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00098670 -
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT02100423 -
Curcumin and Cholecalciferol in Treating Patients With Previously Untreated Stage 0-II Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Terminated |
NCT00303966 -
Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia
|
Phase 2 | |
Active, not recruiting |
NCT01351896 -
Lenalidomide and Vaccine Therapy in Treating Patients With Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT00112593 -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
|
N/A | |
Completed |
NCT01024010 -
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 2 | |
Completed |
NCT01789255 -
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Active, not recruiting |
NCT01361711 -
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
|
Phase 2 | |
Completed |
NCT00918723 -
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
|
Phase 1/Phase 2 | |
Completed |
NCT00003620 -
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Terminated |
NCT02309515 -
Lenalidomide in Improving Immune Response to Vaccine Therapy in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Monoclonal B Cell Lymphocytosis
|
Phase 2 | |
Active, not recruiting |
NCT02213913 -
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
|
Phase 1/Phase 2 | |
Completed |
NCT01269385 -
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Completed |
NCT01649791 -
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia
|
N/A |